SCHEDULE 13G/A: Perceptive Advisors Reduces Stake in Contineum Therapeutics

Perceptive Advisors and affiliates report a reduced beneficial ownership of 3.2% in Contineum Therapeutics, Inc. Class A Common Stock.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G.
• The Reporting Persons beneficially own 699,486 shares of Contineum Therapeutics, Inc. Class A Common Stock.
• This ownership represents 3.2% of the Class A Common Stock outstanding.
• The percentage is based on 21,625,223 shares of Class A Common Stock outstanding as of July 31, 2025, as reported in the Issuer's Form 10-Q filed on August 8, 2025.
• Perceptive Advisors serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors.
• The Reporting Persons certify that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reduction in beneficial ownership by a significant institutional investor, implying a decreased stake below the 5% reporting threshold. While they still hold shares, the reduction is typically viewed unfavorably.

Positives

• Perceptive Advisors, a prominent investment firm, continues to hold a significant stake in Contineum Therapeutics, indicating some level of continued interest in the company.

Negatives

• The filing, being Amendment No. 3 and reporting a stake of 3.2%, indicates that the Reporting Persons have reduced their beneficial ownership below the 5% threshold, which is generally perceived as a negative signal by the market.

Risks

• The reduction in beneficial ownership by a significant institutional investor like Perceptive Advisors could signal a decrease in confidence or a reallocation of capital, potentially impacting investor sentiment.
• The certification states that the securities are not held for the purpose of changing or influencing control, which means the Reporting Persons are unlikely to engage in activist investor actions to drive change.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the issuer's future performance or operations.

Management Comments

• Joseph Edelman, Managing Member of Perceptive Advisors LLC and Perceptive Life Sciences Master Fund, Ltd., certified the information set forth in the statement.

Industry Context

This filing reflects a change in institutional investor positioning within the biotechnology or pharmaceutical sector, where Contineum Therapeutics operates. Such changes are closely watched by the market as indicators of investor sentiment towards specific companies or the sector as a whole.

Stakeholder Impact

• Shareholders: The reduction in a significant institutional stake could lead to negative investor sentiment and potentially impact the stock price.
• Management: May need to address investor concerns regarding the reduction in institutional ownership.

Key Dates

Recommendation

While the reduction in Perceptive Advisors' stake below 5% is a negative signal, the filing itself does not provide enough fundamental information about Contineum Therapeutics' operations, financials, or future prospects to warrant a strong buy or sell recommendation. Investors should 'hold' and await further operational updates or financial reports from the company to make a more informed decision, while acknowledging the potential negative sentiment from this ownership change.

Keywords

Contineum Therapeutics, Perceptive Advisors, Joseph Edelman, Schedule 13G, Beneficial Ownership, Institutional Investor, Stock Ownership, Biotechnology, Healthcare Investment